Transient receptor potential canonical 3 inhibitor Pyr3 improves outcomes and attenuates astrogliosis after intracerebral hemorrhage in mice. by Munakata, Masaya et al.
Title
Transient receptor potential canonical 3 inhibitor Pyr3
improves outcomes and attenuates astrogliosis after
intracerebral hemorrhage in mice.
Author(s)
Munakata, Masaya; Shirakawa, Hisashi; Nagayasu, Kazuki;
Miyanohara, Jun; Miyake, Takahito; Nakagawa, Takayuki;
Katsuki, Hiroshi; Kaneko, Shuji
CitationStroke (2013), 44(7): 1981-1987
Issue Date2013-07
URL http://hdl.handle.net/2433/187123






The TRPC3 inhibitor Pyr3 improves outcomes and attenuates astrogliosis 
after intracerebral hemorrhage in mice 
Masaya Munakata MS; Hisashi Shirakawa, PhD; Kazuki Nagayasu, PhD; Jun 
Miyanohara BS; Takahito Miyake BS; Takayuki Nakagawa, PhD; Hiroshi Katsuki, 
PhD; Shuji Kaneko, PhD 
From Department of Molecular Pharmacology, Graduate School of Pharmaceutical 
Sciences, Kyoto University (M.M., H.S., K.N., J.M., T.M., T.N., S.K.,) and Department 
of Chemico-Pharmacological Sciences, Graduate School of Pharmaceutical Sciences, 
Kumamoto University (H.K.,). 
 
Correspondence to:  
Shuji Kaneko, PhD;  
Department of Molecular Pharmacology, Graduate School of Pharmaceutical Sciences, 
Kyoto University. 46-29 Yoshida-shimoadachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan,  
Tel: +81-75-753-4541; Fax: +81-75-753-4542; E-mail; skaneko@pharm.kyoto-u.ac.jp 
 
Cover title: Protective effect of TRPC3 inhibition against ICH 
Number of figures: 6; supplementary figures: 4; tables: 0 ; words: 5012 
Keywords: intracerebral hemorrhage, inflammation, astrocyte, TRPC channel, TRPC3, 
Pyr3, 
Subject code: [43] Acute Cerebral Hemorrhage 
 2 
Abstract 
Background and purpose: Intracerebral hemorrhage (ICH) stems from the rupture of 
blood vessels in the brain, with the subsequent accumulation of blood in the 
parenchyma. Increasing evidence suggests that blood-derived factors induce excessive 
inflammatory responses that are involved in the progression of ICH-induced brain injury. 
Thrombin, a major blood-derived factor, leaks into the brain parenchyma upon 
blood-brain barrier (BBB) disruption and induces brain injury and astrogliosis. 
Furthermore, thrombin dynamically upregulates transient receptor potential canonical 3 
(TRPC3) channel, which contributes to pathological astrogliosis through a feed-forward 
upregulation of its own expression. The present study investigated whether Pyr3, a 
specific TRPC3 inhibitor, can improve functional outcomes and attenuate astrogliosis 
after ICH in mice. 
Methods: Male C57BL6 mice received an intracerebral infusion of collagenase or 
autologous blood to induce ICH. Pyr3 was given both intracerebroventricularly and 
intraperitoneally after ICH induction. ICH-induced brain injury was evaluated by 
quantitative assessment of neurological deficits, brain swelling and injury volume after 
ICH. Astrocyte activation was evaluated by immunohistochemical assessment of 
changes in S100 protein expression. 
Results: Neurological deficits, neuronal injury, brain edema, and astrocyte activation 
were all significantly improved by administration of Pyr3. Moreover, delayed 
administration of Pyr3 at 6 h or 1 day following blood or collagenase infusion, 
respectively, also improved the symptoms. 
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Conclusions: Pyr3, a specific inhibitor of TRPC3, reduced the perihematomal 
accumulation of astrocytes and ameliorated ICH-induced brain injury. Therefore, 




Intracerebral hemorrhage (ICH) is a subtype of stroke with high morbidity and 
mortality.
1
 Although several therapeutic strategies for management of ICH are currently 
in clinical practice,
1
 virtually none are aimed at neuroprotection. Basic researches have 
demonstrated that various drugs that possess antioxidative, anti-inflammatory or 
neurotrophic/neuroprotective properties produce therapeutic effects on ICH animal 
models,
2, 3
 however effective drug therapies for ICH are yet unavailable. 
Modulation of inflammatory processes mediated by astrocytes, neutrophils, and so 
on may provide an opportunity for restricting the expansion of ICH-induced tissue 
damage.
3,4
 Astrocytes accumulate in the perihematomal region
5
 and induce toxic edema, 
provoke inflammation, release cytotoxins, and form scars following ICH.
6
 Moreover, 
neutrophils, macrophages, and microglia are major central nervous system sources of 
cytokines, chemokines, and other immunomolecules
4 
and are thought to provoke 
secondary brain damage after ICH. 
Transient receptor potential (TRP) channels are formed by homomeric or 
heteromeric tetramers of six subtypes of TRP proteins that constitute six subfamilies: 
the TRP-ankyrin transmembrane protein 1 (TRPA1), TRP-canonical (TRPC), 
TRP-melastatin (TRPM), TRP-mucolipin (TRPML), TRP-polycystin (TRPP), and 
TRP-vanilloid (TRPV) subfamilies.
7
 There are seven TRPC channel isoforms that 
function as homotetrameric or heterotetrameric cation channels. At least one isoform is 
expressed in almost every tissue, where it facilitates voltage-independent Ca
2+
 entry in 
response to calcium store depletion induced by receptor stimulation.
8
 TRPC3 channels 
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are directly activated by diacylglycerol
9
 and underlie the store-operated channels 
observed in many cell types. We previously showed that thrombin, a predominant 
blood-derived factor, induced functional activation of astrocytes via opening of the 
TRPC3 channel in human astrocytoma cell lines
10
 and rat cultured astrocytes.
11
 
Although systemic administration of argatroban, a direct thrombin inhibitor, 
significantly reduced brain edema after ICH,
12
 the effect of TRPC3 inhibition per se has 
not yet been clarified in an in vivo model of ICH. 
In the present study, we investigated whether Pyr3, a selective TRPC3 inhibitor, 
would attenuate brain injury and inflammatory response after in the 
collagenase/autologous blood infusion mouse models of ICH.
13
 It is clearly 
demonstrated that Pyr3 directly binds TRPC3 channel protein, selectively inhibits 
TRPC3 channel activity and can improve TRPC3-related diseases such as cardiac 
hypertrophy.
14 
In addition, Pyr3 reduced Ca
2+
 responses in wild-type acini to the same 
extent as deletion of Trpc3 and had no effect on the Ca
2+





suggesting that Pyr3 is a useful tool for clarification of TRPC3 functions and for 
treatments of TRPC3-mediated diseases. Our data suggest that TRPC3 is involved in the 
development of brain injury after ICH, implicating TRPC3 as a new therapeutic target 
for the prevention of secondary brain injury and neurological deficits after stroke.
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Materials and methods 
 
Induction of ICH and Pyr3 treatment 
All experiments were conducted in accordance with the ethical guidelines of the Kyoto 
University Animal Research Committee. Male C57BL/6J mice (8–13 weeks of age) 
weighing 21–28 g were used to produce the collagenase3 and autologous blood infusion 
ICH models.
16
 Animals were maintained at constant ambient temperature (22°C  1°C) 
under a 12 h light/dark cycle. After intraperitoneal injection of 50 mg/kg pentobarbital, 
mice were placed in a stereotaxic frame. A 30-gauge needle was inserted through a burr 
hole on the skull into the striatum (stereotaxic coordinates: 2.3 mm lateral to the midline, 
0.2 mm anterior to the bregma, and 3.5 mm below the skull). In the collagenase infusion 
model, ICH was induced by microinfusion pump-mediated injection of 0.025 U 
collagenase type VII (Sigma, MO, USA) in 0.5 μL phosphate buffered saline (PBS) at a 
constant rate of 0.20 μL/min. In the autologous blood infusion model, ICH was induced 
by injection of 5 μL autologous blood from the tail vein at a constant rate of 2 μL/min. 
The injection was terminated and 2.5 min later, 10 μL autologous blood was injected at 
a constant rate of 2 μL/min. Body temperature was measured with a rectal probe and 
maintained at 37°C after surgery. 
Pyr3 was suspended in 10% HCO-60 at a concentration of 4 mmol/L and 
intracerebroventricularly administered just one time at a concentration of 1, 10, or 
20 nmol/5 μL at 5 min after the induction of ICH. Thereafter, Pyr3 was intraperitoneally 
administered at a concentration of 2, 20, or 40 mg/kg, twice per day unless otherwise 
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noted. In post-treatment studies, intracerebroventricular administration of Pyr3 was 
performed at 24 or 48 h after collagenase injection or at 6 h after blood injection, 
followed by intraperitoneal administration. The mice were randomly assigned to 
receive vehicle alone or varying doses of Pyr3. All behavioral and histological 
experiments and their subsequent evaluation were performed by an experimenter 
blinded to the identity of the treatment groups. 
 
Behavioral Tests 
Neurological and sensorimotor functions were evaluated via the neurological deficit 
scoring (NDS) system, rotarod test, and rope grip test at 1, 3, and 7 days after surgery. 
In the NDS system, mice were scored by using a 28-point NDS system.
17
 The tests 
included body symmetry, gait, climbing, circling behavior, front limb symmetry, 
compulsory circling, and whisker response. Each point was graded from 0 to 4. 
Maximum deficit score was 28. 
In the rotarod test, mice were placed on a rotarod cylinder, and the duration for 
which the mouse remained on the rotarod was recorded. The rotation speed was slowly 
increased from 4–40 revolutions/min within a period of 3 min. The trial was ended if 
the animal fell off the rotarod or gripped the device and spun around for two or more 
consecutive revolutions. Animals were trained in advance before induction of ICH.  
In the rope grip test, mice were placed midway on a string between two supports 
and rated as follows: 0, falls off; 1, hangs onto string by one or both forepaws; 2, same 
as for 1, but attempts to climb onto string; 3, hangs onto string by one or both forepaws 
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plus one or both hind paws; 4, hangs onto string by forepaws and hind paws plus tail 
wrapped around string; and 5, escapes to the supports.
18
 The final score was the average 
of five trials. 
 
Hemorrhagic injury and hemispheric enlargement analysis 
Twenty micrometer coronal sections were cut with a cryostat and stored at −80°C prior 
to staining with Nissl. Sections were digitized and analyzed with the use of Image J 
software. The hemorrhagic injury area was calculated by quantifying the Nissl 
staining-negative area in each section, and the hemorrhagic injury volume was 
computed by summation of the Nissl staining-negative areas multiplied by the interslice 
distance (200 μm). Brain edema was measured on the basis of hemispheric enlargement 
at the bregma, which was calculated according to the following formula: [(ipsilateral 
hemisphere volume − contralateral hemisphere volume)/contralateral hemisphere 
volume] × 100%. 
 
Immunohistochemistry 
Three days after ICH, mice were anesthetized with pentobarbital and perfused 
transcardially with PBS (10 mL), followed by 4% paraformaldehyde (10 mL). Brains 
were isolated and fixed in 4% paraformaldehyde for 3 h and then soaked in 15% sucrose 
overnight at 4°C. After freezing, brains were cut into 20 μm thick sections, and five 
sections around the injection site were collected every 200 μm and mounted onto slides. 
After rinsing with PBS containing 0.1% Triton X-100 (tPBS), specimens were treated 
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with tPBS-containing blocking serum for 1 h at room temperature and then incubated 
with rabbit anti-S100 antibody (1:400, Dako, Tokyo, Japan), rabbit anti-Iba1 antibody 
(1:500, Wako, Osaka, Japan) and rat anti Gr1/Ly6G antibody (1:300, R&D Systems, 
MN, USA) overnight at 4°C. After rinsing with PBS, specimens were incubated with 
Alexa Fluor 594 donkey anti-rabbit IgG (1:200, Invitrogen, CA, USA) or Alexa Fluor 
594 goat anti-rat IgG (1:200 Invitrogen) for 1 h at room temperature. The average 
number of S100 and Iba1-positive cells at the perihematomal area and Gr1-positive 
cells in the hematoma per 640 × 640 μm2 was counted for at least two independent 




Data are presented as the mean ± the SD. For comparisons among multiple groups, 
one-way or two-way analysis of variance followed by a post hoc Bonferroni test was 
used to determine significant differences. Differences between two groups were 




Effect of Pyr3 on hematoma formation and neurological deficits in the collagenase 
infusion ICH model 
ICH is accompanied by hematoma formation and characteristic behavioral deficits. To 
assess whether Pyr3 affects hematoma formation, we first compared the size of 
hematomas in vehicle and Pyr3-treated mice at 6 h after the induction of ICH in the 
striatum by collagenase injection. No difference was observed in hematoma formation 
between groups (Fig. 1A). To evaluate whether Pyr3 influenced recovery from 
neurologic deficits, various behavioral experiments were conducted. As a result, the 
NDS of vehicle-treated mice was found to increase substantially at 1–7 days after 
collagenase injection. Pyr3 administration substantially improved the NDS at all time 
points examined (Fig. 1B). 
In the rotarod test, induction of ICH resulted in substantial performance deficits in 
vehicle-treated mice, as indicated by a decrease in the latency to fall. Pyr3 treatment 
significantly prevented the decrease at 3 days after ICH (Fig. 1C). A decrease in rope 
climbing performance was also evident after ICH in the rope grip test, but Pyr3 
treatment had a tendency to improve the test score (Fig. 1D). Pyr3 administration alone 
did not cause any neurological adverse effect including gait abnormality (data not 




Effect of Pyr3 on ICH-induced neuronal loss and brain edema 
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The effect of Pyr3 was evaluated in relation to the hemorrhagic injury volume and 
hemispheric enlargement of the injured brain, which both increased after ICH due to 
neuronal loss and brain edema, respectively. Pyr3 prevented the increase in hemorrhagic 
injury volume (Fig. 2A–C) and hemispheric enlargement (Fig. 2D) at 3 days after 
injury. 
 
Intracerebrovebtricular vs. intraperitoneal administration of Pyr3 
Next, we evaluated the efficacy of intraperitoneal vs. intracerebroventricular 
administration of Pyr3 for treatment of ICH. Intracerebroventricular administration 
alone had a tendency to improve motor function in the rotarod or rope grip test but not 
intraperitoneal alone (Supplementary Fig. 1B, C). On the other hand, both the NDS and 
hemorrhagic injury volume were slightly but significantly improved at day 3 after ICH 
(Supplementary Fig. 1A, D). However, the best protection was afforded by the 
combined intraperitoneal/intracerebroventricular route. Therefore, this method of Pyr3 
administration was employed for the remainder of the study. 
 
Concentration-dependent actions of Pyr3 
The concentration-dependence of Pyr3 was next examined following combined 
intracerebroventricular/intraperitoneal administration of the drug (1, 10, or 20 nmol/5 µl 
intracerebroventricular, and 2, 20, or 40 mg/kg intraperitoneal). The lowest drug dose (1 
nmol/5 µl intracerebroventricular and 2 mg/kg intraperitoneal) yielded no significant 
differences between vehicle and Pyr3-treated mice (Fig. 3). However, the hemorrhagic 
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injury volume, NDS, running performance in the rotarod test, and rope grip score were 
all improved in a concentration-dependent manner. 
 
Delayed administration of Pyr3 
To assess the therapeutic time window for Pyr3 administration, Pyr3 was administered 
to mice at 1 or 2 days after ICH induction. Drug administration at 2 days after ICH did 
not protect mice against ICH-induced injury; however, drug administration at 1 day 
after ICH significantly decreased hemorrhagic injury volume and the NDS, and had a 
tendency to improve motor function in the rotarod and rope grip test (Fig. 4). 
 
Reduction in perihematomal accumulation of astrocytes in Pyr3-treated mice 
We have previously shown that TRPC3 contributes to pathological activation of 
astrocytes. To investigate the influence of TRPC3 inhibition on astrocyte behavior in 
vivo, we examined the perihematomal accumulation of activated astrocytes at 1, 3, and 
7 days after ICH via immunohistochemical staining for S100 protein. The number of 
S100-positive astrocytes in the perihematomal area was increased at 1 day after ICH 
and remained elevated throughout the course of the experiment, whereas Pyr3 partially 
prevented the increase (Fig. 5A, B). Moreover, we assessed the accumulation of 
microglia/macrophages and neutrophils using by anti-Iba1 and anti-Gr1 antibodies, 
respectively, at 1, 3, and 7 days after ICH. The number of Iba1-positive cells in the 
perihematomal area was increased after ICH and peaked at 3-7 days after ICH, which 
was significantly inhibited in that of Pyr3-treated mice (Supplementary Fig. 2). The 
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number of Gr1-positive cells in the hematoma was increased after ICH and peaked at 1 
day after ICH, whereas they did not appear at 7 days. There was no difference in the 
number of Gr1-positive cells between vehicle and Pyr3-treated group (Supplementary 
Fig. 3). 
 
Effect of Pyr3 in the autologous blood infusion ICH model 
We next investigated the actions of Pyr3 in the autologous blood infusion ICH model. 
Hematoma formation was comparable between vehicle and Pyr3-treated mice at 6 h 
after ICH (Fig. 6A). The NDS increased in vehicle-treated mice after autologous blood 
infusion, but Pyr3 treatment significantly prevented the increase (Fig. 6B). In the 
rotarod and rope grip tests, induction of ICH in vehicle-treated mice resulted in a 
substantial decline in performance (Fig. 6B). This decline was also prevented by Pyr3 
(Fig. 6B). 
Furthermore, the therapeutic time window for Pyr3 administration after autologous 
blood infusion was assessed by administration of the drug at 6 h after ICH. Even such 
delayed administration of Pyr3 significantly decreased the NDS at 24 and 72 h after 
ICH and significantly increased the rope grip test score at 24 h (Fig. 6C). 
Moreover, the distribution of activated astrocytes in the perihematomal area was 
examined via immunohistochemistry at 1, 3, and 7 days post-ICH. The number of 
S100-positive cells increased at day 1 and remained elevated for 7 days in 
vehicle-treated mice, whereas Pyr3 administration significantly prevented the increase 
at days 1 and 3 (Supplementary Fig. 4). 
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Discussion 
This study demonstrates for the first time that Pyr3, a selective TRPC3 inhibitor, 
ameliorated reactive astrogliosis and neurologic deficits resulting from collagenase and 
autologous blood infusion-induced ICH, whereas the drug did not affect hematoma 
formation. In addition, delayed administration of Pyr3 after the onset of brain injury was 
effective in both ICH models. These results suggest that Pyr3 can improve 
neuropathological outcomes after ICH in mice. 
Emerging evidence suggests that activated astrocytes contribute to brain tissue 
damage after ICH. For example, matrix metalloproteinase (MMP) 9
20
 and aquaporin 
(AQP) 4 and 9
21
 are upregulated in activated astrocytes and stimulate the formation of 
edema after ICH. Moreover, activated astrocytes release S100B into the serum, which is 
significantly correlated with brain edema formation and hematoma volume in ICH
22
 and 
hemorrhagic transformation in ischemia.
23
 Furthermore, ICH-associated astrocyte 
reactivity is increased in aged compared with young rats,
5
 while arundic acid, a specific 
inhibitor of S100B synthesis, mitigates delayed infarct expansion and neurologic 
deficits.
24
 Thus, excessive activation of astrocytes is likely to influence clinical 
outcomes following stroke. 
Our previous investigations demonstrated that thrombin-induced stimulation of 
proteinase-activated receptor-1 in astrocytes resulted in the opening of the TRPC3 
channel as detected by Ca
2+
 imaging, the influxed Ca
2+
-dependent activation of specific 
signaling molecules, de novo TRPC3 protein synthesis, feed-forward amplification of 
TRPC3 expression, and finally, functional astrogliosis in vitro.
11
 These results imply 
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that thrombin leaked from ruptured blood vessels can activate astrocytes through 
TRPC3 channels in vivo. This hypothesis is strongly supported by our present results 
demonstrating that the selective TRPC3 inhibitor Pyr3 suppressed reactive astrogliosis 
and ameliorated functional recovery in mouse ICH model. Hence, suppression of 
astrocyte activation may ameliorate secondary injury after ICH. 
It is however necessary to consider that Pyr3 treatment inhibits TRPC3 channels 
expressed in multiple cell types, including neurons, immune cells and endothelial cells. 
Accordingly, the inhibitory effect of Pyr3 against ICH might be attributed to a specific 
blockade of not only astrocyte but also monocyte/macrophage or neutrophil TRPC3 




It has been reported that TRPC3 mediates ATP-induced vascular cell adhesion 
molecule 1 expression and resultant monocyte recruitment to the endothelium
25
 and 
minocycline, an inhibitor of microglial/macrophage activation, can reduce the 
blood-brain barrier (BBB) damage and edema following ICH,
26
 implying that 
Pyr3-mediated suppression of monocytes and endothelial cell functions via TRPC3 
might contribute to the amelioration of ICH-induced brain injury. On the other hands, 
stimulation of phagocytosis in microglia/macrophage leads to the promotion of 
hematoma resolution, thereby the suppression of neuronal damage after ICH,
27
 and 
macrophage TRPC3 contributes to survival signaling and efferocytic properties,
28
 
raising a fear that Pyr3 can exacerbate secondary injury after ICH to disrupt the 
physiological function of monocyte/macrophage. Furthermore, astrocytic accumulation 
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was comparatively early and peaked at day 1 after ICH, whereas microglial/macrophage 
accumulation was gradual and peaked at day 3-7, indicating that activation of astrocytes 
appears to precede that of microglial/macrophage in this ICH model. Taking into 
consideration that activated astrocytes can facilitate distant microglial activation in CNS 
disease,
29
 the observed suppression of microglia/macrophages might be just a result of 
Pyr3-mediated suppression of astrocytes.  
It has been reported that TRPC3 is also involved in the regulation of NADPH 
oxidase in the human neutrophil-like cell line
30
 and neutrophil depletion reduces the 
BBB breakdown, axon injury, and astrocytic and microglia/macrophage responses after 
intracerebral hemorrhage,
31
 raising the possibility that the inhibitory effect of Pyr3 may 
be due to a blockade of neutrophil TRPC3. Since our present data show that Pyr3 does 
not affect the infiltration of neutrophils after ICH, the observed effects of Pyr3 appear to 
be independent of neutrophils. 
Meanwhile, TRPC3 is required to promote cerebellar granule neuron survival
32
 and 
for metabotropic glutamate receptors-dependent synaptic transmission and motor 
coordination.
19
 Therefore, the blockade of TRPC3 in neurons by Pyr3 may negatively 
impact neurological recovery post-ICH. Although Pyr3 alone did not show any 
neurological adverse effect in this study, development of a more selective, cell 
type-specific TRPC3 inhibitor may preserve the inhibitory actions against astrocytes 
while sparing neurons, further improving outcomes after ICH. 
In this study, Pyr3 was administered through a combined 
intracerebroventricular/intraperitoneal route. Although intraperitoneal administration 
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alone weakly but significantly improved ICH-induced injury, the intracerebroventricular 
route was more effective, and the combined route was the most efficacious of all. These 
results are reminiscent of experiments with minocycline
33
 and suggest that Pyr3 does 
not readily cross the BBB.  
In the collagenase infusion ICH model (but not the autologous blood infusion 
model), the BBB was disrupted, and bleeding continued for up to 24 h.
34
 Although 
hematoma formation was comparable in vehicle vs. Pyr3-treated mice subsequent to 
collagenase treatment, Pyr3 substantially improved collagenase-induced behavioral 
deficits and attenuated reactive astrogliosis. These results suggest that Pyr3 can 
ameliorate secondary brain injury stemming from ICH, without affecting the enzyme 
activity of collagenase or the integrity of the BBB. 
In conclusion, the present findings indicate that thrombin released into the brain 
following ICH activates astrocytes via TRPC3, setting off a chain of events that 
ultimately induces neuronal death and neurological deficits. Thus, cell type-specific 
inhibitors of TRPC3 may constitute a novel class of therapeutic drugs for ICH. 
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Figure Legends 
Figure 1. Effect of Pyr3 on hematoma formation and neurological deficits in 
collagenase infusion ICH model mice. A, structural formula of Pyr3 and representative 
images of coronal sections obtained 6 h after collagenase injection showing 
similarly-sized hematomas in vehicle and Pyr3-treated mice. B–D, summarized data of 
neurological deficits, as assessed by the NDS (B), rotarod test (C), and rope grip test 
(D). Pyr3 was administered intracerebroventricularly (20 nmol) and intraperitoneally 
(40 mg/kg twice per day). n = 5–6; *P < 0.05, ***P < 0.001 vs. vehicle. 
 
Figure 2. Effect of Pyr3 on injury volume and edema after collagenase-induced ICH. 
A–B, representative images of Nissl-stained coronal sections obtained 3 days after 
collagenase injection in vehicle-treated mice (A) and Pyr3-treated mice (B). C, 
summarized data of injury volume (dashed line in panels A and B). D, summarized data 
of hemispheric enlargement in the ipsilateral compared with the contralateral 
hemisphere. Pyr3 was administered intracerebroventricularly (20 nmol) and 
intraperitoneally (40 mg/kg twice per day). n = 6–9; ***P < 0.001 vs. vehicle. 
 
Figure 3. Dose-dependent effects of Pyr3 on neurological deficits and brain injury at 3 
days after collagenase-induced ICH. Summarized data of neurological deficits, as 
assessed by the NDS (A), rotarod test (B), rope grip test (C), and hemorrhagic injury 
volume (D). Pyr3 was administered intracerebroventricularly (i.c.v., 1, 10, or 20 nmol) 
and intraperitoneally (i.p., 2, 20, or 40 mg/kg twice per day). n = 4; *P < 0.05, **P < 
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0.01, ***P < 0.001 vs. vehicle. 
 
Figure 4. Therapeutic time window of Pyr3 effects on neurological deficits and brain 
injury at 3 days after collagenase-induced ICH. Summarized data of neurological 
deficits, as assessed by the NDS (A), rotarod test (B), rope grip test (C), and 
hemorrhagic injury volume (D). Pyr3 was administered intracerebroventricularly (i.c.v., 
20 nmol) and intraperitoneally (i.p., 40 mg/kg twice per day). n = 5–6; *P < 0.05, ***P 
< 0.001 vs. vehicle. 
 
Figure 5. Inhibitory effect of Pyr3 on the number of astrocytes in the perihematomal 
area of collagenase-induced ICH mice. A, representative images of S100-positive cells. 
B, summarized data of the number of S100-positive cells. Pyr3 was administered 
intracerebroventricularly (20 nmol) and intraperitoneally (40 mg/kg twice per day). n = 
5–8; *P < 0.05 vs. vehicle. 
 
Figure 6. Effect of Pyr3 on autologous blood-induced ICH injury. A, representative 
images of coronal sections obtained 6 h after blood infusion showing similarly-sized 
hematomas in vehicle and Pyr3-treated mice. B, schematic representation of the 
experimental schedule (upper left) and summarized data of neurological deficits, as 
assessed by the NDS (upper right), rotarod test (lower left), and rope grip test (lower 
right). C, therapeutic time window of Pyr3. Schematic representation of the 
experimental schedule (upper left) and summarized data of neurological deficits, as 
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assessed by the NDS (upper right), rotarod test (lower left), and rope grip test (lower 
right). Pyr3 was administered intracerebroventricularly (i.c.v., 20 nmol) and 
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Supplemental Fig. 4 
 
Supplemental Figure legends 
 
Supplementary Figure 1. Effect of different routes of Pyr3 administration on ICH-induced 
injury at 3 days after collagenase injection. A–C, summarized data of neurological deficits, as 
assessed by the NDS (A), rotarod test (B), rope grip test (C), and hemorrhagic injury volume 
(D). Pyr3 was administered intracerebroventricularly (i.c.v., 20 nmol) and/or intraperitoneally 
(i.p., 40 mg/kg twice per day). n = 4; *P < 0.05, **P < 0.01, ***P < 0.001 vs. vehicle. 
 
Supplementary Figure 2. Inhibitory effect of Pyr3 on the number of microglia/macrophages in 
the perihematomal area of collagenase-induced ICH mice. A, representative images of 
Iba1-positive cells. B, summarized data of the number of Iba1-positive cells. Pyr3 was 
administered intracerebroventricularly (20 nmol) and intraperitoneally (40 mg/kg twice per day). 
n = 6–7; **P < 0.01 vs. vehicle. 
 
Supplementary Figure 3. Null effect of Pyr3 on the number of neutrophils in the hematomal 
area of collagenase-induced ICH mice. A, representative images of Gr1-positive cells. B, 
summarized data of the number of Gr1-positive cells. Pyr3 was administered 
intracerebroventricularly (20 nmol) and intraperitoneally (40 mg/kg twice per day). n = 3–5. 
 
Supplementary Figure 4. Inhibitory effect of Pyr3 on the number of astrocytes in the 
perihematomal area of autologous blood-induced ICH mice. A, representative images of 
S100-positive cells. B, summarized data of the number of S100-positive cells. Pyr3 was 
administered intracerebroventricularly (i.c.v., 20 nmol) and intraperitoneally (i.p., 40 mg/kg 
twice per day). n = 3–6; *P < 0.05, **P < 0.01 vs. vehicle. 
 
